Gilead's Trodelvy Fails First-Line Breast Cancer Trial, But Hope Remains
Update: 2025-11-08
Description
Gileads cancer drug, Trodelvy, failed to meet its primary goal in a late-stage trial for a specific type of metastatic breast cancer, causing a dip in the companys stock. Despite not significantly improving progression-free survival, theres an early trend suggesting patients on Trodelvy might live longer than those on chemotherapy. Gilead plans to continue the trial and explore Trodelvys potential in other cancer types.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
